← SynDRA
ALOFANIB
SynDRA canonical compound SYN0040061 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | FGFR2 |
|---|
| Mechanism of action | fgfr inhibitor |
|---|
| Indication | ovarian cancer |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- FGFR2 INHIBITOR
- fgfr inhibitor
Cross-references
Synonyms
- 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid
- RPT-835(alofanib)
- UNII-LQX7RFK8MZ
- RPT 835
- RPT835
- LQX7RFK8MZ
- ES000835
- Alofanib [INN]
- Alofanib(RPT835)
- Syn007154
- CHEMBL4594436
- SCHEMBL18660613
- AMY16650
- BCP31905
- EX-A2731
- MFCD30533418
- NSC790182
- s8754
- Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-
- NSC-790182
- SB19665
- AC-31695
- AK668992
- AS-56846
- HY-17601
- CS-0014684
- Q27283135
- 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid
- alofanibum
- RefChem:110963
- C19H15N3O6S
- Alofanib?
- Alofanib (RPT835)
- ALOFANIB [WHO-DD]
- orb1302071
- SCHEMBL29627123
- SCHEMBL29729859
- GTPL11622
- MPC88866
Look up ALOFANIB in the interactive SynDRA portal →